Ocugen outlines plans for three BLA filings in next three years amid global gene therapy expansion [Seeking Alpha]
Ocugen, Inc. (OCGN)
Company Research
Source: Seeking Alpha
CEO Shankar Musunuri highlighted the company's rapid progress on its modifier gene therapy platform, noting "in just over 3 years, we brought our lead candidate, OCU400, from initial Phase 1/2 dosing to nearing Phase 3 enrollment Quick Insights Ocugen is on track for BLA submissions for three products, with commercial manufacturing readiness emphasized and partnerships being pursued to maximize patient reach for a planned 2027 launch. Recent financing extends Ocugen's runway through at least Q2 2026, and possibly into 2027 if warrants are exercised, covering operating expenses, R&D, and commercial readiness investments. OCU400's Phase 3 trial is nearing enrollment completion with a BLA filing planned in 2026 and anticipated commercialization in 2027; OCU410ST aims for pivotal trial enrollment completion by Q1 2026 and a BLA submission in the first half of 2027. Recommended For You More Trending News
Show less
Read more
Impact Snapshot
Event Time:
OCGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCGN alerts
High impacting Ocugen, Inc. news events
Weekly update
A roundup of the hottest topics
OCGN
News
- How the Narrative Surrounding Ocugen Is Shifting After New Licensing and Analyst Developments [Yahoo! Finance]Yahoo! Finance
- Ocugen CEO to Present at NobleCon21—Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference [Yahoo! Finance]Yahoo! Finance
- Ocugen CEO to Present at NobleCon21—Noble Capital Markets’ Twenty-First Annual Emerging Growth Equity ConferenceGlobeNewswire
- How Recent Developments Are Rewriting the Story for Ocugen [Yahoo! Finance]Yahoo! Finance
- Ocugen Inc (OCGN) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges [Yahoo! Finance]Yahoo! Finance
OCGN
Earnings
- 8/1/25 - In-Line
OCGN
Sec Filings
- 11/5/25 - Form 10-Q
- 11/5/25 - Form 8-K
- 10/31/25 - Form SCHEDULE
- OCGN's page on the SEC website